Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Symptoms of persistent asthma for at least one year
History of asthma treatments including "as-needed" inhaled short-acting beta-agonists (albuterol/salbutamol); stable doses of inhaled corticosteroids (ICS), combination ICS/long-acting (inhaled) Beta2-adrenergic agonist (LABA) and/or oral asthma controller(s)
Must be able to discontinue or taper asthma controlling medications while receiving Montelukast
No history of smoking or no smoking for at least 1 year, with a smoking history of no more than 10 pack-years
Body Mass Index (BMI) of 15 kg/m\^2 to 40 kg/m\^2.
Females must not be pregnant (negative serum human chorionic gonadotropin test) or breastfeeding and must not plan to become pregnant for the duration of the study, including the post-treatment follow-up period
Women and male participants of reproductive potential must agree to use adequate contraception for the duration of the study
You may not be if
Evidence of another active pulmonary disorder such as bronchiectasis or chronic obstructive pulmonary disease (COPD)
Unable to perform acceptable, repeatable spirometry
History of myocardial infarction, congestive heart failure, or uncontrolled cardiac arrhythmia within 3 months of screening visit
Major surgical procedure(s) within 4 weeks of screening visit
Blood donation within 2 weeks of screening visit
Treatment in an emergency room for asthma (within 4 weeks) or hospitalization for asthma or respiratory condition within 2 months of screening visit
Evidence of active sinus disease within 2 weeks of screening visit
Upper respiratory infection (viral or bacterial) within 1 month of screening visit
History of a psychiatric disorder within 3 months of screening visit
History of human immunodeficiency virus (HIV)
Unstable disease of the ophthalmologic, neurological, hepatic, renal, connective tissue, genitourinary, gastrointestinal, cardiovascular or hematologic systems
History of cancer (except for successfully treated basal and squamous cell carcinomas of the skin) within 5 years of screening visit
Uncontrolled hypertension
Participation in a clinical trial involving an investigational drug within 4 weeks of screening visit
Hypersensitivity or intolerance to inhaled beta-agonists and/or leukotriene inhibitors or any of their ingredients, including lactose and galactose
Known sensitivity to or has not had previous exposure to aspirin or non-steroidal anti-inflammatory drugs
Clareo Health | Study of MK-1029 in Participants With Persistent Asthma That Cannot Be Controlled With Montelukast (MK-1029-015)
